Biomarker & Intervention Discovery
Chronic Urticaria (CSU)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionSpontaneous remission at 1 year: ~50%; at 5 years: ~65-70%; but 10-15% remain chronic beyond 5 years; remission…
Best-intervention remissionOmalizumab (anti-IgE): complete symptom resolution in 36-44% at 12 weeks (GLACIAL, ASTERIA trials); high-dose…
Gap sizeModerate — omalizumab is transformative but not accessible as first-line; many patients on inadequate antihistamine…
Primary barrieraccess/practice
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous remission at 1 year: ~50%; at 5 years: ~65-70%; but 10-15% remain chronic beyond 5 years; remission followed by relapse common
Best-intervention remission
Omalizumab (anti-IgE): complete symptom resolution in 36-44% at 12 weeks (GLACIAL, ASTERIA trials); high-dose antihistamines (4x standard dose): 50-60% symptom control; cyclosporine for antihistamine-refractory: 50-60% response; dupilumab for CSU: 73% UAS7 ≤6 at 24 weeks (Phase 3 LIBERTY-CSU CUPID 2023)
Gap size
Moderate — omalizumab is transformative but not accessible as first-line; many patients on inadequate antihistamine doses or antihistamine monotherapy long-term
Primary barrier
access/practice
Omalizumab (Xolair) was FDA-approved for CSU in 2014 but remains unavailable as first-line (prior authorisation requiring antihistamine failure first); many patients spend years on sedating antihistamines or systemic OCS; dupilumab (2023 Phase 3 data) adds a second biologic option
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Chronic Urticaria (CSU)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."